Purdue Frederick Company's 2007 guilty plea and sentencing brought a federal case over OxyContin's promotion to a negotiated resolution, imposing substantial financial penalties while exposing how warnings about the drug's risks had preceded its commercial success. The agreement followed pressure on prosecutors and a narrowing of the charges initially contemplated; its penalties became a landmark action, but did not resolve the broader questions of corporate accountability and public oversight raised by the case.

Warnings Before the Case

The evidence that framed the controversy reached back to the U.S. Food and Drug Administration's 1995 review of OxyContin. The new-drug application described how crushing a tablet could release the drug immediately rather than gradually, noted withdrawal symptoms in several clinical-trial patients, and reported that 68 percent of the oxycodone could be recovered from a crushed pill and injected. Purdue Pharma later maintained that it had not known of OxyContin's abuse problems until February 2000. The earlier review made that claim difficult to reconcile with information already documented in the approval record.

The approval summary itself urged restraint in marketing, cautioning against excessive competitive promotion. Yet the book describes the drug's promotion as anything but restrained. The discrepancy between the warnings in the application and the subsequent marketing became part of the larger question the prosecution had to address: not simply whether OxyContin was abused, but what the company had known and how it had represented the drug.

The federal case also included evidence of falsified charts created by Purdue. The charts mattered because the prosecution concerned the company's claims about OxyContin, not only the individual harms associated with the medication. In the account of the plea, this documentary evidence sits alongside the earlier regulatory record: one showed warnings available before widespread controversy, the other formed part of the government's case about the company's conduct.

Investigation and Negotiation

By the fall of 2006, federal prosecutors were considering charges more serious than misbranding, including mail fraud, wire fraud, and money laundering. A memo to John Brownlee reflected the possibility that the small-town prosecution team had assembled enough evidence to pursue felony charges against both the company and senior executives. The eventual agreement was therefore the product of a contest over how much of the case would survive negotiation, not simply an initial decision to impose a fine.

The financial proposals shifted dramatically. Purdue first offered $10 million, while the government's initial proposal was $1 billion. The account describes the charges as being watered down as the case moved through the United States Department of Justice headquarters, amid lobbying by Purdue's representatives, including Rudy Giuliani. The negotiations took place against a background of direct pressure on Brownlee: in 2005, Purdue's lawyers had challenged his investigative tactics to then–Deputy Attorney General James Comey, who raised concerns with the prosecutor. Brownlee drove to Washington to explain his strategy and was told to return to Virginia and continue the case.

The decisive deadline arrived in October 2006, on the night before the plea agreement was set to expire. At a Purdue lawyer's request, a senior Justice Department official called Brownlee at home to urge an extension. Brownlee refused to prolong the negotiations. Purdue accepted the agreement that night rather than face the prospect of more serious charges or a jury trial in western Virginia, where OxyContin's problems had become widely known. The settlement thus ended a moment of acute pressure, but the account emphasizes that the threat of further prosecution had already been reduced during the process.

Sentencing and Penalties

The 2007 sentence included a $634.5 million fine against Purdue Frederick Company, Inc. Its specified components included $276.1 million forfeited to the federal government; $160 million to resolve claims by federal and state programs over false Medicaid and other government health-care claims; $130 million for private civil claims; $5.3 million for Virginia's Medicaid Fraud Control Unit; and $20 million for Virginia's prescription monitoring program. Purdue was also to pay the maximum statutory criminal fine of $500,000. These amounts directed money to government, public programs, and private claims, making the settlement a substantial financial consequence even as its structure left open questions about what punishment corporate misconduct should bring.

Senior executives also received individual fines. Michael Friedman was fined $19 million, Howard Udell $8 million, and Paul Goldenheim $7.5 million; each was assessed an additional $5,000. The three executives avoided prison. The outcome set financial penalties against the executives but did not impose incarceration, a contrast that shaped public response to the sentencing.

Families affected by OxyContin addressed the court as part of the proceedings. Victor Del Regno testified about his son, Andrew, bringing a family's loss into a hearing otherwise structured around pleas, penalties, and legal findings. Their testimony gave the sentencing a human scale that the corporate figures could not supply: the case was not only about a company and its executives, but about people whose families believed the drug's promotion had helped bring devastation into their lives.

The sentencing judge's limited authority is another part of the account's assessment of the result. Financial consequences and restrictions affecting the executives' participation in taxpayer-funded health-care programs followed, but the judge's hands were tied by the terms and legal constraints of the case. Later restrictions were contested and modified; the executives' exclusion from such programs, initially set at twenty years, was reduced, with the account reporting an eight-year period in the end. The distinction between what the case exposed and what the court could impose underscores the limits of a plea agreement as a form of accountability.

Wider Questions of Oversight

The case unfolded amid concerns about the relationship between pharmaceutical companies, regulators, and pain-advocacy organizations. A later investigation reported that FDA regulators and pharmaceutical executives had held private annual meetings through an industry-funded nonprofit beginning in 2002. The practice of enriched enrollment, developed in that setting, allowed drug companies to exclude study participants who responded poorly to a medication, potentially making trial results more favorable to approval. This reporting did not itself establish the terms of Purdue's plea, but it added to the book's portrait of an oversight system vulnerable to conflicts between public protection and industry influence.

Investigative reporting also documented that the American Pain Society and the American Academy of Pain Medicine supported expanded opioid use for long-term chronic pain while receiving millions of dollars from drug manufacturers. A Senate investigation led by Chuck Grassley and Max Baucus in 2012 targeted the American Pain Foundation, Purdue, and other organizations and companies. Its findings remained sealed in the Senate Finance Committee's office, despite calls for their release. The unresolved inquiry echoed the limits of the 2007 resolution: the guilty plea and penalties established a legal reckoning, but did not make the wider network of influence and oversight fully visible or answer every question about responsibility.